Acquired epidermodysplasia verruciformis: clinical presentation and treatment update

Int J Dermatol. 2022 Nov;61(11):1325-1335. doi: 10.1111/ijd.15857. Epub 2021 Aug 17.

Abstract

Acquired epidermodysplasia verruciformis (AEV) is a form of epidermodysplasia verruciformis (EV) that is most commonly found in immunocompromised or immunosuppressed patients. EV is commonly associated with human papillomavirus (HPV), which is often found in EV and AEV lesions. Clinical presentation of AEV in patients with organ transplantation, HIV+, congenital HIV+, hematological diseases, and other iatrogenic immunosuppression are reviewed. Treatment options include topical cidofovir, topical retinoids, topical imiquimod, topical glycolic acid, HPV 9-valent vaccine, acitretin, improving cellular immunity, and changing transplant medication to mycophenolate mofetil.

Publication types

  • Review

MeSH terms

  • Acitretin / therapeutic use
  • Cidofovir / therapeutic use
  • Epidermodysplasia Verruciformis* / diagnosis
  • Epidermodysplasia Verruciformis* / drug therapy
  • HIV Infections* / complications
  • Humans
  • Imiquimod / therapeutic use
  • Mycophenolic Acid / therapeutic use
  • Papillomaviridae
  • Papillomavirus Infections* / complications
  • Vaccines* / therapeutic use

Substances

  • Vaccines
  • Mycophenolic Acid
  • Cidofovir
  • Acitretin
  • Imiquimod